Valitacell, a biotech offering cell-based manufacturing, and Solentim, a provider of cell line development instrumentation, have formed a new collaboration to enable earlier identification of biological candidates and to accelerate the development of breakthrough medicines.
 
Valitacell’s novel in-line analytical profiling technologies and its data driven/machine learning approach, together with Solentim’s innovative image-driven liquid handling and cell measurement technology, will look to transform current workflows, creating a streamlined, automated platform which synergizes precise cell manipulations, attribute-rich profiling of clones and earlier decision making.
 
“This collaboration combines our expertise in both biotherapeutics and emergent cellular therapy, and will optimize the process of drug discovery. We look forward to working in partnership with Solentim as we continue to discover and develop life-saving medicines that improve patients’ lives,” said Terry McWade, chief executive officer, Valitacell.
 
Ian Taylor, chief commercial officer, Solentim, said, “We are delighted to be collaborating with Valitacell. This combination of technologies will provide a further component to our unique integrated solution for accelerating stable cell line development workflows. It will provide significant benefits for richer clone information and earlier decision-making on the best candidates to progress.